Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 218 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... May 10, 2021 CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns October 11, 2019 Study Advances Fertility Preservation Approach for Male Cancer Survivors April 24, 2019 Opinion: ‘Beating cancer means beating it for everyone’ January 29, 2021 Load more HOT NEWS Rescue Cat Alerts Mom to Breast Cancer by “Aggressively” Cuddling Her... Fatiga relacionada con el cáncer: Lo que las personas con cáncer... Truck Driver Saves People From Bus Fire On Christmas Eve NCI Launches New Resource for Specimens and Data from Cancer Clinical...
